Orange Book Listing Eligibility: Must it be the Active Ingredient Itself? Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC [Trial] * This article is a trial and does not provide legal advice. All information should be re-verified for its accuracy and current applicability.
It appears a court case regarding Orange Book listings has been released. The following is another trial.
Case Name: Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC
Court: United States Court of Appeals for the Federal Circuit (CAFC)
Date of Decision: December 20, 2024
https://cafc.uscourts.gov/opinions-orders/24-1936.OPINION.12-20-2024_2439730.pdf
Case Overview
This case is a patent dispute concerning patents held by Teva Branded Pharmaceutical Products R&D, Inc. (hereinafter, Teva) and the appropriateness of listing them in the Orange Book. Teva had listed several patents related to an inhaler containing albuterol sulfate (salbutamol sulfate), an asthma medication, in the Orange Book. Meanwhile, generic drug manufacturer Amneal Pharmaceuticals of New York, LLC (hereinafter, Amneal) was seeking approval for a generic drug containing the same ingredient and argued that Teva's patents were obstructing the FDA approval process.
Amneal pointed out that Teva's patents were related to the inhaler device or its components rather than the active ingredient itself, and requested that these patents be removed from the Orange Book.
Patents in Dispute
The patents in dispute in this case include the following:
U.S. Patent No. 8,132,712 ("the '712 patent")
U.S. Patent No. 9,463,289 ("the '289 patent")
U.S. Patent No. 9,808,587 ("the '587 patent")
U.S. Patent No. 10,561,808 ("the '808 patent")
U.S. Patent No. 11,395,889 ("the '889 patent")
Representative Claim is Claim 1 of the '712 patent.
A metered-dose inhaler device comprising:
(a) a canister containing a pharmaceutical formulation comprising albuterol sulfate as an active pharmaceutical ingredient;
(b) a metering valve coupled to the canister for dispensing a metered dose of the pharmaceutical formulation; and
(c) a mouthpiece for delivering the metered dose to a patient.
This claim defines the configuration of the inhaler device (canister, metering valve, mouthpiece) and does not directly protect the chemical structure or properties of the active ingredient albuterol sulfate itself.
Comparison of Active Ingredient and Patent Claims
Albuterol sulfate specific structure:
Molecular Formula:
Chemical Name: (RS)-1-(tert-butylamino)-3-(4-hydroxyphenyl)-2-propanol sulfate
Structural characteristics: An aromatic ring with a phenolic group (-OH) and activity as a β2-adrenergic receptor agonist.
In contrast, Teva's patent claims primarily target the physical configuration of the inhaler device. Although it is stated that it "contains" the active ingredient, the structure or mechanism of action of the active ingredient itself is not included in the scope of the patent.
Decisions of the Lower Court and the Federal Circuit Court of Appeals
The U.S. District Court for the District of New Jersey upheld Amneal's argument, ruling that Teva's patents did not cover the active ingredient itself. Consequently, it ordered these patents to be removed from the Orange Book.
Teva appealed this decision to the CAFC, but the CAFC also upheld the lower court's ruling. The court determined that patents to be listed in the Orange Book should be limited to those that directly cover the drug's active ingredient or its method of use, and that patents concerning the configuration of an inhaler device are outside the scope of the list.
Significance of the Judgment
This judgment is significant as it clarifies the criteria for listing patents in the Orange Book and has the following implications:
Clarification of criteria: Patents listed in the Orange Book must directly protect the active ingredient or its method of use.
Promotion of competition: Prevents brand-name drug manufacturers from using device-related patents to delay the market entry of generic drug manufacturers.
Promotion of generic drug approval: Avoids delays in FDA approval caused by inappropriate patent listings.
Conclusion
This judgment is an important precedent that promotes fair market competition and influences the patent strategies between brand-name and generic drug manufacturers. It is considered to provide guidance for the patent linkage and Orange Book operations currently being discussed in Japan.